Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The butanol fraction of Ziziphus mucronata root (ZMBF) is a botanical research extract derived from the roots of *Ziziphus mucronata* Willd. (family Rhamnaceae), a plant traditionally used in Nigerian folk medicine for the treatment of diabetes. Preclinical studies, primarily conducted by academic researchers at the University of KwaZulu-Natal and Ahmadu Bello University, have investigated ZMBF for its antidiabetic potential in type 2 diabetes models. The extract functions as an inhibitor of **alpha-glucosidase**, an enzyme critical for carbohydrate digestion, with an IC50 of 1.41 μg/ml. In vivo research in diabetic rat models has shown that oral administration of ZMBF can reduce blood glucose levels, improve glucose tolerance, and increase serum insulin and liver glycogen, although it may not ameliorate all metabolic parameters associated with the disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butanol fraction of Ziziphus mucronata root.